A phase 2 randomized controlled trial of 120 Chinese adults with overweight or obesity (no diabetes) tested once-weekly subcutaneous BGM0504 — a dual GLP-1R/GIPR agonist — at 5 mg, 10 mg, and 15 mg doses over 24 weeks. The 15 mg arm produced mean body weight reduction of 18.33% versus a 0.13% gain in placebo, with waist circumference shrinking 14.38 cm. Effects were strongly dose-dependent (all p < 0.0001 vs. placebo), and pharmacokinetics showed a linear dose-exposure relationship, suggesting predictable scaling.
These results place BGM0504 in direct competitive territory with tirzepatide (Mounjaro), the approved dual GLP-1/GIP agonist that achieved roughly 15–22% weight loss in SURMOUNT trials at 15 mg — though cross-trial comparisons carry known methodological hazards. What distinguishes this trial is its exclusively non-diabetic Chinese population, a demographic underrepresented in major incretin obesity trials, and where baseline body-fat distribution and drug metabolism may differ meaningfully. The 18.3% figure at 15 mg is clinically impressive for a phase 2 trial with only 120 participants, but the small cohort limits power to detect rare safety signals. Drug-related adverse events hit 93.1% in the highest-dose group — predominantly GI events — flagging tolerability as a development hurdle. No withdrawals occurred, which is favorable. This is confirmatory of the dual-incretin mechanism's potency rather than paradigm-shifting, but validates BGM0504 as a pipeline candidate worth phase 3 scrutiny in Asian populations.